Abstract
Multidrug resistance (MDR) mediated by P-glycoprotein is one of the best characterized transporter-mediated barriers to successful cancer chemotherapy. In an attempt to find MDR-reversing agents, a series of novel acridine derivatives were synthesized and evaluated for their in vitro antiproliferative activities against K562 and K562/ADM cells. Some of these compounds showed superior MDR-reversing activities than Amsacrine, the reference compound. Structureactivity relationships (SAR) of these compounds indicated that the N, N-diethylamine moiety had an affect on the in vitro antiproliferative activity. Interestingly, the compounds bearing N, N-diethylamine moiety showed higher growthinhibitory activity against K562/ADM cells than K562 cells. The high duplex DNA binding affinity and inhibition of topoisomerase of these acridine compounds are maintained which were confirmed by fluorescent quenching and DNA topoisomerase II cleavage assay, respectively. Moreover, several compounds were examined for their ability to increase the accumulation of rhodamine 123 in K562 and K562/ADM cells, and the result suggested that they may be inhibitors for P-glycoprotein. Our study suggested that acridine framework is a potentially interesting scaffold for developing novel MDR-reversing agents.
Keywords: Acridine derivative, structure-activity relationships, P-glycoprotein, multidrug resistance.
Current Medicinal Chemistry
Title:Synthesis, Structure-Activity Relationship and Biological Activity of Acridine Derivatives as Potent MDR-Reversing Agents
Volume: 20 Issue: 32
Author(s): Jianhong Wang, Tianwei Luo, Shaobin Li, Yahong Zhhang, Chaojie Wang and Jin Zhao
Affiliation:
Keywords: Acridine derivative, structure-activity relationships, P-glycoprotein, multidrug resistance.
Abstract: Multidrug resistance (MDR) mediated by P-glycoprotein is one of the best characterized transporter-mediated barriers to successful cancer chemotherapy. In an attempt to find MDR-reversing agents, a series of novel acridine derivatives were synthesized and evaluated for their in vitro antiproliferative activities against K562 and K562/ADM cells. Some of these compounds showed superior MDR-reversing activities than Amsacrine, the reference compound. Structureactivity relationships (SAR) of these compounds indicated that the N, N-diethylamine moiety had an affect on the in vitro antiproliferative activity. Interestingly, the compounds bearing N, N-diethylamine moiety showed higher growthinhibitory activity against K562/ADM cells than K562 cells. The high duplex DNA binding affinity and inhibition of topoisomerase of these acridine compounds are maintained which were confirmed by fluorescent quenching and DNA topoisomerase II cleavage assay, respectively. Moreover, several compounds were examined for their ability to increase the accumulation of rhodamine 123 in K562 and K562/ADM cells, and the result suggested that they may be inhibitors for P-glycoprotein. Our study suggested that acridine framework is a potentially interesting scaffold for developing novel MDR-reversing agents.
Export Options
About this article
Cite this article as:
Wang Jianhong, Luo Tianwei, Li Shaobin, Zhhang Yahong, Wang Chaojie and Zhao Jin, Synthesis, Structure-Activity Relationship and Biological Activity of Acridine Derivatives as Potent MDR-Reversing Agents, Current Medicinal Chemistry 2013; 20 (32) . https://dx.doi.org/10.2174/09298673113209990187
DOI https://dx.doi.org/10.2174/09298673113209990187 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
Current Molecular Pharmacology Dendrimers: A Class of Polymers in the Nanotechnology for the Delivery of Active Pharmaceuticals
Current Pharmaceutical Design Targeting Cell Death and Survival Receptors in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Cationic Lipophilic Radiotracers for Functional Imaging of Multidrug Resistance
Current Radiopharmaceuticals The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer
Current Topics in Medicinal Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders Emerging Technologies, Recent Developments, and Novel Applications for Drug Metabolite Identification
Current Drug Metabolism Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation as Potential Alzheimers Therapies
Current Bioactive Compounds Urate Transport: Regulators of Serum Urate Levels in Humans
Current Rheumatology Reviews Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs
Current Cancer Drug Targets Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors
Current Medicinal Chemistry Tetrazole Derivatives as Promising Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy
Current Stem Cell Research & Therapy Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry To Preliminarily Evaluate The Anticancer Activiy of 1,2-di(quinazolin-4- yl)diselane Against MDA-MB-435 Cells in vitro
Letters in Drug Design & Discovery Screening of NO Inhibitor Release Activity from Soft Coral Extracts Origin Palu Bay, Central Sulawesi, Indonesia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Drug Delivery Letters